Group Financial Results as of March 31st 2024 Approved, Continued Growth and EBITDA Margin Expansion, Euro 500 Million Share Buy-Back Program Launched Nanotech Investing
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer Nanotech Investing
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update Nanotech Investing
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update Nanotech Investing
Longeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 Nanotech Investing
Sona's Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model Technology Investing
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer Nanotech Investing
Sona Nanotech Secures Grant Funding to Support Intellectual Property Strategy and Development Technology Investing
